EGFR and non-small cell lung carcinoma: According to retrospective findings, patients with advanced epidermal growth factor receptor (EGFR) mutant NSCLC may benefit from combining SBRT with ongoing TKI therapy, which prolongs PFS and overall survival [11,12,13].